|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/51 | (2006.01) |
| A61K 31/517 | (2013.01) | ||
| A61K 31/437 | (2006.01) | ||
| A61K 9/5138 | (2013.01) | ||
| A61K 31/437 | (2013.01) | ||
| A61K 31/44 | (2006.01) | ||
| A61K 31/444 | (2013.01) | ||
| A61K 31/4545 | (2006.01) | ||
| A61K 31/44 | (2013.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/517 | (2006.01) | ||
| A61K 31/4439 | (2013.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/4545 | (2013.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61P 9/10 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61K 9/5161 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 9/5192 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61K 9/5146 | (2013.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 9/10 | (2018.01) |
| (11) | Number of the document | 3181128 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17155689.7 |
| Date of filing the European patent application | 2013-01-11 | |
| (97) | Date of publication of the European application | 2017-06-21 |
| (45) | Date of publication and mention of the grant of the patent | 2023-03-08 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 1250015 | 2012-01-13 | SE | |
| 201261586187 P | 2012-01-13 | US | |
| 1251160 | 2012-10-12 | SE | |
| 201261713120 P | 2012-10-12 | US |
| (72) |
BRISANDER, Magnus , SE
DEMIRBÛKER, Mustafa , SE
JESSON, Gérald , SE
MALMSTEN, Martin , SE
DÉRAND, Helene , SE
|
| (73) |
XSpray Pharma AB (publ) ,
Gunnar Asplunds Allé 32, 171 63 Solna,
SE
|
| (54) | NILOTINIB PHARMACEUTICALCOMPOSITION |
| NILOTINIB PHARMACEUTICALCOMPOSITION |